Results 51 to 60 of about 29,370 (221)

Risk factor identification and prevention of osteoporosis in the primary care setting [PDF]

, 2006
On one of her visits, MB Borg, a 54 year old lady, showed concern about her risk of developing osteoporosis. Lately, she had been listening to a series of radio and TV programmes on this matter where particular emphasis was put on bone density scans. She
De Gabriele, Patricia
core  

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability. [PDF]

PLoS ONE, 2016
Treatment of osteoporosis with alendronate sodium has several challenges. The first challenge is the low bioavailability. The second main challenge is side effects, which include oesophageal ulceration.
Khaled Mohamed Hosny
doaj   +1 more source

Development of Bone Targeting Drugs. [PDF]

, 2017
The skeletal system, comprising bones, ligaments, cartilage and their connective tissues, is critical for the structure and support of the body. Diseases that affect the skeletal system can be difficult to treat, mainly because of the avascular cartilage
Alméciga-Díaz, Carlos J., Mackenzie, William G., Mason, Robert W., Orii, Tadao, Sawamoto, Kazuki, Stapleton, Molly, Tomatsu, Shunji   +6 more
core   +2 more sources

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study

BMC Musculoskeletal Disorders, 2010
Background A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian ...
Papaioannou Alexandra, Grima Daniel T, Airia Parisa, Ioannidis George, Adachi Jonathan D   +4 more
doaj   +1 more source

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis [PDF]

, 2010
The structural basis of the antifracture efficacy of strontium ranelate and alendronate is incompletely understood. We compared the effects of strontium ranelate and alendronate on distal tibia microstructure over 2 years using HR-pQCT.
René Rizzoli, Michel Laroche, Marc-Antoine Krieg, Isolde Frieling, Thierry Thomas, Pierre Delmas, Dieter Felsenberg, A Parfitt, E Seeman, PD Delmas, S Boutroy, A Laib, A Laib, E Seeman, UA Liberman, SE Papapoulos, RG Russel, PM Chavassieux, M Arlot, R Recker, R Balena, M Arlot, TC Brennan, E Bonnelye, N Chattopadhyay, GJ Atkins, SD Bain, PJ Meunier, JY Reginster, D Black, A Laib, G Boivin, G Boivin, KA Davis, P Garnero   +34 more
core   +3 more sources

Vascular Calcification: Mechanisms, Models, and Therapies

iNew Medicine, EarlyView.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu, Shu Yang, Ziyi Chen, Xiaoxiao Yang, Zhen Liang, Yuanli Chen   +5 more
wiley   +1 more source

Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. [PDF]

, 2012
Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis.
Guan, Min, Jia, Junjing, Lam, Kit S, Lane, Nancy E, Liu, Ruiwu, Meng, Liping, Nolta, Jan, Panganiban, Brian, Ritchie, Robert O, Shahnazari, Mohammad, Yao, Wei, Zhou, Ping   +11 more
core   +1 more source

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra [PDF]

, 2009
Introduction Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone.
Allen, Matthew R., Burr, David B., Diab, Tamim   +2 more
core   +1 more source